APA (7th ed.) Citation

Miles, D. W., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Campone, M., . . . Trask, P. (2021). Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Annals of oncology, 32(10), . https://doi.org/10.1016/j.annonc.2021.06.024

Chicago Style (17th ed.) Citation

Miles, David W., et al. "Final Results from the PERUSE Study of First-line Pertuzumab Plus Trastuzumab Plus a Taxane for HER2-positive Locally Recurrent or Metastatic Breast Cancer, with a Multivariable Approach to Guide Prognostication." Annals of Oncology 32, no. 10 (2021). https://doi.org/10.1016/j.annonc.2021.06.024.

MLA (9th ed.) Citation

Miles, David W., et al. "Final Results from the PERUSE Study of First-line Pertuzumab Plus Trastuzumab Plus a Taxane for HER2-positive Locally Recurrent or Metastatic Breast Cancer, with a Multivariable Approach to Guide Prognostication." Annals of Oncology, vol. 32, no. 10, 2021, https://doi.org/10.1016/j.annonc.2021.06.024.